Synapse - David Nemirovsky

Results (46)

Barriers to chimeric antigen receptor T-cell therapy

Research Letter

Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
JAMA Oncology (2025)

Fulltext@MSK | Save

CAR and ALL hematotox scores predict toxicity and outcomes among recipients of brexucabtagene autoleucel for R/R ALL in the real world outcomes collaborative of CAR-T in adult ALL (ROCCA) consortium

Meeting Abstract

Valtis, Y.; Lin, C. Y.; Nemirovsky, D.; Devlin, S.; Rejeski, K.; Shah, N. N.; Nair, M. S.; Jeyakumar, N.; Miller, K.; Zhang, A.; more...
Transplantation and Cellular Therapy (2025)

Fulltext@MSK | Save

Health-related values discussions with patients undergoing allogeneic and autologous stem cell transplant: Feasibility and acceptability of an early primary palliative care intervention

Journal Article

Cohen, A. G.; Cho, C.; Patterson, E.; Magaldi, J.; Doga, T.; Naputo, K.; Alvarez, K.; Giles, E.; Yang, G.; Hoque, A.; more...
Transplantation and Cellular Therapy (2025)

Fulltext@MSK | Save

NGS MRD negativity on day 28 after brexu cel in adults with R/R ALL is associated with favorable progression free survival

Meeting Abstract

Valtis, Y. K.; Nemirovsky, D.; Devlin, S. M.; Roloff, G. W.; Aldoss, I.; Jeyakumar, N.; Miller, K.; Zhang, A.; Sutherland, K. C.; Advani, A. S.; more...
Blood (2024)

Fulltext@MSK | Save

Derivation and external validation of a venous thromboembolism risk prediction model in patients with acute lymphoblastic leukemia receiving asparaginase therapy

Meeting Abstract

Anderson, D. R.; Gangaraju, R.; Sedhom, W.; Hamulyak, E. N.; Wang, T. F.; O'Dwyer, K. M.; Carney, B. J.; Muthiah, C.; Liedtke, M.; Badar, T.; more...
Blood (2024)

Fulltext@MSK | Save

Imaging predictors of intracerebral hemorrhage in patients with brain tumors treated with anticoagulation

Meeting Abstract

Barnea, R.; Naftali, J.; Hamulyak, E. N.; Peseski, A. M.; Wang, T. F.; Kreuziger, L. B.; Iyengar, V.; Carney, B. J.; Özdemir, B.; Serrano, R. D. C.; more...
Blood (2024)

Fulltext@MSK | Save

Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)

Meeting Abstract

Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
Blood (2024)

Fulltext@MSK | Save

Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies

Meeting Abstract

Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
Blood (2024)

Fulltext@MSK | Save

Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma

Meeting Abstract

Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
Blood (2024)

Fulltext@MSK | Save

Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction

Meeting Abstract

Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
Blood (2024)

Fulltext@MSK | Save